Seach Medical: How Much Financial Flexibility Really Remains After the 2026 Dividend

Where financial flexibility should really be measured

The main article argued that Seach ended 2025 with relatively strong liquidity even though reported earnings weakened. This follow-up isolates the question most easily blurred inside that headline: how much genuinely flexible cash is left once operating cash that can repeat is separated from cash released out of working capital, and what the dividend approved in March 2026 does to that reading.

Two cash frames matter here at the same time. The first is an all-in cash flexibility frame, because the issue is real financing freedom after actual cash uses, not accounting profit alone. The second is a narrower normalized cash generation frame, meant to test how much of 2025 operating cash came from repeatable activity once the receivables release is stripped out. The gap between those two readings is the core of the thesis.

The short answer: the dividend does not create a liquidity event today. It does raise the proof bar. At the end of 2025 the group had NIS 8.1 million of cash and NIS 20.2 million of marketable securities, together NIS 28.3 million of gross liquidity, alongside NIS 22 million of unused bank-credit lines. The group also met its financial covenants, and beyond the legal framework it disclosed no external dividend restrictions. After a dividend of about NIS 6 million, gross liquidity falls to roughly NIS 22.3 million. That is still not a tight funding position, but it is already a smaller cushion that requires 2026 to prove the cash balance is being rebuilt out of repeatable operating generation.

The subtle point is that the dividend looks much more threatening if one looks only at the net cash and cash-equivalent line, which stood at NIS 7.5 million after deducting bank credit. That is an incomplete reading. The company also manages liquidity through money-market funds and marketable securities, so the right liquidity frame here is NIS 28.3 million, not NIS 7.5 million. Still, that is not a reason to dismiss the payout. A NIS 6 million dividend removes about 21% of gross year-end liquidity. It does not break the balance sheet, but it clearly narrows the margin for error.

How much of 2025 cash really came from the business

Operating cash flow reached NIS 17.5 million in 2025. The number is real, and it is also strong relative to net profit of only NIS 0.35 million. But anyone reading it as fully clean operating cash misses two different things. Almost half of the number leaned on an NIS 8.344 million decrease in trade receivables, and the company itself attributed that mainly to better payment terms. In other words, part of the story is collections, not only profitability.

But that is not the whole picture. Most of that receivables release was nearly absorbed by the rest of working capital: inventory increased by NIS 3.108 million, other receivables rose by NIS 2.259 million, suppliers declined by NIS 1.443 million, other payables fell by NIS 0.320 million, and net taxes paid consumed another NIS 0.886 million. After netting those items, the total working-capital contribution was only about NIS 1.0 million. That matters. 2025 was not simply a year of working-capital release. But it also cannot be presented as a year in which the business generated NIS 17.5 million of fully clean cash untouched by one-offs or timing effects.

On a narrower test, if only the receivables release is removed, about NIS 9.2 million of operating cash flow remains before investment, interest, lease cash and shareholder distributions. That is still a positive base. So the overly harsh read, that all of 2025 cash flow was just a one-off collections exercise, would be too negative. But it is also not a generous cushion for an industry where inventory, customer credit and demand can move quickly.

The gap between weak net profit and stronger cash flow also explains why the year looked healthier in the cash account than in the income statement. The non-cash adjustments included an NIS 8.036 million goodwill impairment, alongside NIS 3.633 million of tax expense and NIS 3.911 million of depreciation and amortization. So the cash balance did not weaken as much as reported earnings suggest, but it would also be wrong to read the cash flow as a direct translation of much cleaner operating economics.

The all-in bridge: what is left after the real cash uses

In an all-in cash frame, the right question is not how much cash came in from operations, but how much of it was still left after the cash uses that are hard to argue away: lease principal, interest, reported investment and the dividend actually paid. I leave the move into money-market funds outside this bridge because those balances were still available liquidity on the balance-sheet date. Counting them both as a use and as part of the year-end cushion would double count the same cash.

The numbers are sharp. After NIS 2.976 million of lease principal, NIS 1.353 million of cash interest, NIS 1.101 million of reported investment in fixed assets, and NIS 3.967 million of dividend paid in 2025, about NIS 8.1 million was left from the year’s operating cash flow. After adding the dividend approved in March 2026, the pro forma remainder drops to only about NIS 2.1 million.

That is why the 2026 dividend raises the proof bar. It does not create a funding crisis today, because the company would still sit with about NIS 22.3 million of gross liquidity and about NIS 22 million of unused credit lines. But it does tell the market something clear: management is choosing to return capital before it has fully proved that 2025 cash flow is repeatable without another meaningful lift from collections.

It is also worth remembering the balancing fact. Management’s presentation highlighted positive operating cash flow of NIS 5.8 million in the fourth quarter. That is a supportive signal. It says the year did not end in a cash collapse. Still, if 2026 brings cash back into inventory, longer customer days, or another drag in pharmacy profitability, the March dividend will look less like a confidence signal and more like a distribution brought forward ahead of a proof year that has not yet been completed.

What 2026 now has to prove

The first test is collections. The NIS 8.344 million drop in receivables cannot repeat every year. If it is not replaced by cleaner profitability and better inventory turns, operating cash flow will look materially thinner.

The second test is working-capital discipline across the vertical chain. At Seach this is not only a pharmacy issue. Cash can get trapped in cultivation, production, inventory and customer credit almost as quickly as it was released in 2025. That is why 2026 needs to show not merely a one-off improvement in payment terms, but a more durable ability to generate cash across the chain.

The third test is a better match between profit and cash. 2025 showed that the cash account can stay strong even when reported earnings are weak. That is a positive fact. But after a roughly NIS 6 million dividend, the market will no longer be satisfied with simple survival. It will want to see that the vertically integrated platform is starting to produce cleaner net earnings as well, not only cash that still depends in part on working-capital release and non-cash add-backs.

The bottom line is clear. Seach enters 2026 without immediate liquidity stress. That is the positive starting point. But the latest dividend does not lower the proof bar, it raises it. From here, the question is no longer whether the company has enough cushion to distribute cash, but whether the business can rebuild that cushion after the distribution.